2 results
Approved WMORecruiting
Among patients under treatment for depression, we will select 140 persons with IMD. In this specific group of patients, we will test whether celecoxib add-on (400 mg/d) is more effective than placebo in the treatment of depression through a 12-week…
Approved WMORecruiting
Primary:• To compare progression free survival (PFS) between Arm A (ociperlimab in combination with tislelizumab) and Arm B (pembrolizumab followed by placebo) in the Intent to Treat (ITT) Analysis Set as assessed by investigators according to…